P2.17-07 Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis

Authors

B. Halmos, Albert Einstein College of Medicine, Bronx, United States
P. Lammers, Baptist Cancer Center, Memphis, United States
Mehul Patel, Rochester Regional HealthFollow
I. Shapira
L. Shunyakov
D. Slater, Eastern Connecticut Hematology and Oncology Associates, Norwich, United States
C. Labbe
N. Naveh, Jazz Pharmaceuticals, Philadelphia, United States
A. Boccuti, Jazz Pharmaceuticals, Philadelphia, United States
R. Hanvesakul, Jazz Pharmaceuticals, Oxford, United Kingdom
W. Li
B. Rengarajan
F. Badin

Department

Oncology and Hematology

Document Type

Conference Proceeding

Publication Title

Journal of Thoracic Oncology

Conference Name

World Conference on Lung Cancer

Conference Date

2023-09-09 - 2023-09-13

First Page

S381

DOI

10.1016/j.jtho.2023.09.674

Volume

18

Issue

11, Supplement

Publication Date

11-2023

Recommended Citation

Halmos, B., Lammers, P., Patel, M., Shapira, I., Shunyakov, L., Slater, D., Labbe, C., Naveh, N., Boccuti, A., Hanvesakul, R., Li, W., Rengarajan, B., & Badin, F. (2023). P2.17-07 Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis. Journal of Thoracic Oncology, 18 (11, Supplement), S381. https://doi.org/10.1016/j.jtho.2023.09.674